Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.

Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, Garcia-Olmo DC, Nam-Cha SY, Salinas-Sanchez AS, Eng K, Beltran H, Scott DA, Metallo CM, Moscat J, Diaz-Meco MT.

Cancer Cell. 2019 Mar 18;35(3):385-400.e9. doi: 10.1016/j.ccell.2019.01.018. Epub 2019 Feb 28.

PMID:
30827887
2.

Molecular model for neuroendocrine prostate cancer progression.

Chen R, Dong X, Gleave M.

BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24. Review.

PMID:
29569310
3.

Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.

Lee AR, Gan Y, Xie N, Ramnarine VR, Lovnicki JM, Dong X.

Cancer Sci. 2019 Jan;110(1):245-255. doi: 10.1111/cas.13869. Epub 2018 Dec 12.

4.

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.

Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1587. [Epub ahead of print]

5.

SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.

Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y, Collins C, Dong X.

Eur Urol. 2017 Jan;71(1):68-78. doi: 10.1016/j.eururo.2016.04.028. Epub 2016 May 11.

PMID:
27180064
6.

Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.

Lu C, Qie Y, Liu S, Wu C, Zhang Z, Liu R, Yang K, Hu H, Xu Y.

DNA Cell Biol. 2018 Sep;37(9):758-766. doi: 10.1089/dna.2018.4193. Epub 2018 Jul 3.

PMID:
29969286
7.

Polycomb-mediated silencing in neuroendocrine prostate cancer.

Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2015 Apr 3;7:40. doi: 10.1186/s13148-015-0074-4. eCollection 2015.

8.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

9.

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA.

Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130.

10.

PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

Paul A, Gunewardena S, Stecklein SR, Saha B, Parelkar N, Danley M, Rajendran G, Home P, Ray S, Jokar I, Vielhauer GA, Jensen RA, Tawfik O, Paul S.

Cell Death Differ. 2014 Sep;21(9):1469-81. doi: 10.1038/cdd.2014.62. Epub 2014 May 2.

11.

Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer's disease.

Sajan MP, Hansen BC, Higgs MG, Kahn CR, Braun U, Leitges M, Park CR, Diamond DM, Farese RV.

Neurobiol Aging. 2018 Jan;61:225-237. doi: 10.1016/j.neurobiolaging.2017.09.001. Epub 2017 Sep 15.

12.

Def-6, a novel regulator of small GTPases in podocytes, acts downstream of atypical protein kinase C (aPKC) λ/ι.

Worthmann K, Leitges M, Teng B, Sestu M, Tossidou I, Samson T, Haller H, Huber TB, Schiffer M.

Am J Pathol. 2013 Dec;183(6):1945-1959. doi: 10.1016/j.ajpath.2013.08.026. Epub 2013 Oct 3.

13.

Cellular plasticity and the neuroendocrine phenotype in prostate cancer.

Davies AH, Beltran H, Zoubeidi A.

Nat Rev Urol. 2018 May;15(5):271-286. doi: 10.1038/nrurol.2018.22. Epub 2018 Feb 20. Review.

PMID:
29460922
14.

Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.

Santoni M, Conti A, Burattini L, Berardi R, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R.

Biochim Biophys Acta. 2014 Dec;1846(2):630-7. doi: 10.1016/j.bbcan.2014.10.008. Epub 2014 Nov 4. Review.

PMID:
25450825
15.

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA.

Neoplasia. 2013 Jan;15(1):1-10.

16.
17.

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK.

Transl Oncol. 2017 Jun;10(3):357-366. doi: 10.1016/j.tranon.2017.01.011. Epub 2017 Mar 24.

18.

Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.

Chen R, Li Y, Buttyan R, Dong X.

Oncotarget. 2017 Jul 19;8(49):84863-84876. doi: 10.18632/oncotarget.19386. eCollection 2017 Oct 17. Erratum in: Oncotarget. 2018 Jul 3;9(51):29842.

19.

Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.

Cancer Res. 2018 May 15;78(10):2691-2704. doi: 10.1158/0008-5472.CAN-17-3677. Epub 2018 Feb 27.

PMID:
29487201
20.

RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.

Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.

Eur Urol. 2019 Mar 22. pii: S0302-2838(19)30197-6. doi: 10.1016/j.eururo.2019.03.011. [Epub ahead of print]

Supplemental Content

Support Center